Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2024 | $7.00 | Overweight | Piper Sandler |
| 9/30/2024 | $4.00 | Buy | BTIG Research |
| 6/28/2024 | $2.00 | Buy | Rodman & Renshaw |
| 11/20/2023 | Underweight | JP Morgan | |
| 11/9/2023 | Market Perform → Outperform | TD Cowen | |
| 5/10/2023 | $1.50 → $1.00 | Underperform → Hold | Jefferies |
| 2/24/2023 | $3.20 → $1.50 | Hold → Underperform | Jefferies |
| 8/8/2022 | Neutral → Underweight | JP Morgan |
– NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism –– IND-Enabling Studies Underway for NKTR-0165 with First-in-Human Studies Planned in First Half of 2025 -
Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 73.97 percent increase over losses of $(0.73) per share from the same period last year. The company reported quarterly sales of $21.639 million which beat the analyst consensus estimate of $15.342 million by 41.05 percent. This is a 0.21 percent increase over sales of $21.594 million the same period last year.
SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/
SAN FRANCISCO, Aug. 8, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the second quarter ended June 30, 2024. Cash and investments in marketable securities at June 30, 2024 were $290.6 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the third quarter of 2026. "We continue to make excellent progress advancing rezpegaldesleukin in Phase 2 studies in patients with atopic dermatitis and alopecia areata," said
SAN FRANCISCO, Aug. 1, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the second quarter 2024 on Thursday, August 8, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/.
Piper Sandler initiated coverage of Nektar Therapeutics with a rating of Overweight and set a new price target of $7.00
BTIG Research resumed coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $4.00
Rodman & Renshaw initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $2.00
Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh
BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and
SAN FRANCISCO, Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced it has appointed Diana M. Brainard, M.D., as an independent director to its Board of Directors. Dr. Brainard brings over two decades of experience working in the healthcare sector and academia to Nektar. She currently serves as Chief Executive Officer (CEO) of AlloVir, Inc., a leading late clinical stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. "We are very ple
Huntsville-based facility to be spun out as standalone Ampersand portfolio company. Nektar to receive $90 million in total consideration for the business, comprised of $70 million in cash and $20 million equity ownership in new portfolio company. Strategic divestiture allows Nektar to streamline its operations and continue its strategic focus on the development of core R&D programs in immunology. SAN FRANCISCO, Nov. 4, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a definitive agreement to sell its Huntsville, Alabama ma
SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/
- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes - - Biomarker analyses demonstrate plurality of Treg-mediated pathways with potential effect on tissue resident memory T cell populations resulting in sustained efficacy seen in the antigen challenged mouse model and in clinical trials - SAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of rezpegaldesleukin in patients with
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
10-Q - NEKTAR THERAPEUTICS (0000906709) (Filer)
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)